[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-diseases":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,72,0,25,[9,53,83,126,160,186,210,234,270,321,351,378,411,436,463,503,527,558,600,626,649,680,707,734,755],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100559420","phase-3-acoramidis-transthyretin-amyloidosis-prevention-trial-in-the-young-act-early-study-in-asymptomatic-carriers-of-a-pathogenic-ttr-variant-100559420",false,"NCT06563895","Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)","Key Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 75 years of age inclusive.\n* Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M\u002Fp.V50M, V122I\u002Fp.V142I, T60A\u002Fp.T80A, or all other pathogenic TTR variants).\n* Participant's age is within 10 years younger than or older than PADO.\n\nKey Exclusion Criteria:\n\n* Evidence of ATTR-CM or ATTR-PN.\n* Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies.\n* Contraindication to or inability to undergo cardiac magnetic resonance testing.\n* Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy\n* Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.\n* Major surgery within the past 3 months or planned during the next 12 months.\n* Known hypersensitivity to acoramidis.","ALL","18 Years","75 Years",{"count":21,"type":22},587,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.\n\nAmyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN.\n\nAcoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs.\n\nThis study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.",[28,29,30,31,32,33],"Amyloidosis","Amyloid Cardiomyopathy","Transthyretin Amyloidosis","Cardiomyopathies","Heart Diseases","Polyneuropathies",[28,35,36,37,38,39],"ATTR-CM","ATTR-PN","Transthyretin","Amyloid","TTR","RECRUITING","2026-06-25",{"date":43,"type":44},"2026-06-29","ACTUAL",{"date":46,"type":44},"2025-05-12",{"date":48,"type":22},"2032-12",{"name":50,"class":51},"Eidos Therapeutics, a BridgeBio company","INDUSTRY",103,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100615100","phase-2-transition-to-kpl-387-monotherapy-dosing--administration-study-100615100","NCT07288216","Transition to KPL-387 Monotherapy Dosing & Administration Study","A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies","Key Inclusion Criteria:\n\n* Has well-controlled recurrent pericarditis (i.e., including having CRP \\\u003C 0.5 mg\u002FdL within 14 days of Baseline and a pericarditis pain NRS score ≤ 3 at Baseline)\n* Has a documented history of CRP elevation (\\> 1 mg\u002FdL) associated with at least one prior acute pericarditis episode, whether the incident event or any pericarditis recurrence\n* Has received treatment for RP for at least 3 months prior to Baseline with standard therapy(ies) and is currently on a stable dosing regimen including NSAIDs and\u002For colchicine, and\u002For glucocorticoids or an IL-1 pathway inhibitor (anakinra or rilonacept).\n\nKey Exclusion Criteria:\n\n* Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies\n* Has had a pericarditis recurrence in the last 3 months prior to Baseline\n* Has received an investigational drug during the 4 weeks before study drug administration or is planning to receive an investigational drug at any time during the study.\n* Has a history of active or untreated, latent tuberculosis (TB) prior to screening.\n* Has a history of immunodeficiency.\n* Has a history of immunosuppression, including positive human immunodeficiency virus (HIV) test results.\n* Has chest x-ray at Screening or within 12 weeks before first study drug administration, with evidence of malignancy, abnormality consistent with prior or active TB infection or active infection.\n* Has a history of malignancy of any organ system within the past 5 years before Screening (other than a successfully treated non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix).\n* Has a known or suspected current active infection or a history of chronic or recurrent infectious disease (\\> 3 episodes in prior 12 months), including but not limited to, genitourinary infection, chest infection, sinusitis, or skin\u002Fsoft tissue infection.\n* Has had a serious infection, has been admitted to the hospital for an infection, or has been treated for a documented infection requiring antibiotics for a documented infection within 2 weeks prior to first study drug administration.\n* Has had an organ transplant (except corneal transplant performed more than 3 months prior to first study drug administration).\n* In the Investigator's opinion, has any other medical condition that could adversely affect the subject's participation or interfere with study evaluations.","80 Years",{"count":62,"type":22},80,[64],"PHASE2","The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.",[67,32,68],"Recurrent Pericarditis","Pericarditis",[70,71,72,67],"Recurrence","Recurrent","KPL-387","2026-06-18",{"date":75,"type":44},"2026-06-22",{"date":77,"type":44},"2026-03-25",{"date":79,"type":22},"2029-12-31",{"name":81,"class":51},"Kiniksa Pharmaceuticals International, plc",33,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":111,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)",{"count":92,"type":22},1859,[94],"NA","The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[97,32,98,99,100,101,102,103,104,105,106,107,108,109,110],"Coronary Disease","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[112,113,114,115],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","2026-06-15",{"date":118,"type":44},"2026-06-17",{"date":120,"type":44},"2026-06-11",{"date":122,"type":22},"2033-06",{"name":124,"class":51},"Teleflex",1,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100556522","trial-to-evaluate-safety-and-effectiveness-of-mechanical-circulatory-support-in-patients-with-advancing-heart-failure-100556522","NCT06526195","Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure","TEAM-HF","Inclusion Criteria:\n\n1. Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure\n2. LVEF ≤30% and Cardiac Index ≤ 2.5 L\u002Fmin\u002Fm²\n3. Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL\u002Fkg\u002Fmin (or \\\u003C50% of predicted peak VO2 value)\n4. NYHA Class IIIB or NYHA Class IV\n5. Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months\n6. Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant\n7. Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group\n\nRandomization Criteria:\n\n1. Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.\n2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.\n3. mean PAP ≥ 30 mmHg.\n4. The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.\n\nSingle Arm Registry Criteria:\n\n1. Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.\n2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.\n3. mean PAP \\\u003C30 mmHg\n\nExclusion Criteria:\n\n1. Subject is \\\u003C 18 years of age at the time of informed consent.\n2. Dependent on IV inotrope in the last 30 days.\n3. Contra-indications to HM3 LVAS or CardioMEMS HF system.\n4. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.\n5. Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.\n6. Existence of ongoing MCS.\n7. Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.\n8. History of any solid organ transplant.\n9. Psychiatric disease\u002Fdisorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.\n10. Presence of an active, uncontrolled infection.\n11. Complex congenital heart disease.\n12. Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.\n13. History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (\\>1 episode) pulmonary embolism and\u002For deep vein thrombosis.\n14. Planned VAD or Bi-VAD support prior to enrollment.\n15. Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:\n\n    1. An INR ≥ 2.0 not due to anticoagulation therapy\n    2. An eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.\n    3. Biopsy proven liver cirrhosis.\n    4. Need for chronic renal replacement therapy.\n    5. History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 \\\u003C 30% predicted.\n    6. History of cerebrovascular disease with significant (\\> 80%) uncorrected internal carotid stenosis.\n    7. Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.\n16. Any condition other than HF that could limit survival to less than 24 months.\n17. Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.",{"count":134,"type":22},850,[94],"The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.",[138,32,98,139],"Heart Failure","Pulmonary Hypertension",[138,141,142,143,144,145,146,147,148,149],"Left Ventricular Assist Device (LVAD)","Guideline Directed Medical Therapy (GDMT)","Non-inotrope Dependent","Pulmonary Artery Pressure","Hemodynamic Monitoring","Medical Management","CardioMEMS","HeartMate 3 (HM3)","Ambulatory Advanced Heart Failure","2026-06-08",{"date":152,"type":44},"2026-06-10",{"date":154,"type":44},"2024-12-13",{"date":156,"type":22},"2032-09",{"name":158,"class":51},"Abbott Medical Devices",68,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":125},"100474012","testing-virtues-patient-care-sets-in-cardiac-patients-virtues-cardiac-care-100474012","NCT05452356","Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)","Testing of Patient Care Sets and Management of Cardiovascular Conditions Using a Virtual Platform","VIRTUES-CC","Inclusion Criteria:\n\n* Any patient with a cardiovascular condition.\n* Ability to provide informed consent.\n* Proficient in the English language.\n* Access to a device capable of running mobile application.\n* Used mobile technology within the past 3 months.\n\nExclusion Criteria:\n\n* Any medical condition making 1-month survival unlikely.",{"count":169,"type":22},2000,"OBSERVATIONAL","Patients with various cardiac conditions (such as those who experience a heart attack) are increasing in Canada and are in need of appropriate cardiac rehabilitation and care. Many patients do not have access to local in-person cardiac clinics, particularly in rural regions of Canada. A user-friendly digital application with accessible educational resources and recommendations based on the most up to date clinical practice guidelines can help mitigate these issues. VIRTUES is a digital healthcare application that targets 11 modifiable modules as follows:\n\n1. antithrombotic management\n2. lipid management\n3. rate and rhythm control for atrial fibrillation\n4. heart failure care\n5. post myocardial infarction care\n6. blood sugar management\n7. blood pressure management\n8. physical activity\n9. healthy eating\n10. smoking cessation\n11. alcohol reduction\n\nOf the 11 total modules, the first 7 listed provide recommendations in VIRTUES. The remaining 4 (physical activity, healthy eating, smoking cessation and alcohol reduction) consist of simple referrals to existing recommendations (i.e., for healthy eating and physical exercise) and referrals to existing local programs (i.e., for smoking cessation and alcohol reduction). Thus, in this cohort study, the investigators will test the primary 7 modules with 200 patients per module for approximately one month each in order to obtain feedback on the usability of each module. The investigators will also conduct virtual focus group discussions to obtain open ended feedback on the application. This study will provide valuable feedback, which will be used to improve and adapt the VIRTUES platform.",[32,173,174,98,175],"Arrhythmias, Cardiac","Atrial Fibrillation","Pathologic Processes","2026-05-19",{"date":178,"type":44},"2026-05-22",{"date":180,"type":44},"2024-04-18",{"date":182,"type":22},"2028-09-30",{"name":184,"class":185},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":17,"minAge":193,"maxAge":60,"enrollmentInfo":194,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100376770","american-indian-chronic-renal-insufficiency-cohort-study-ai-cric-study-100376770","NCT04185844","American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)","AI-CRIC","Inclusion Criteria:\n\n* Glomerular Filtration Rate (GFR): eGFR of =\\>61\\\u003C80 and microalbuminuria \\> 30 or eGRF of =\\\u003C60 (no microalbuminuria required).\n\nExclusion Criteria:\n\n1. Unable or unwilling to provide informed consent\n2. life expectancy \\\u003C3 years;\n3. institutionalized subjects;\n4. End stage renal disease or renal transplant;\n5. renal cancer;\n6. myeloma;\n7. immunosuppression;\n8. Polycystic kidney disease;\n9. participation in any clinical trial,\n10. current pregnancy\n11. current incarceration.\n12. Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.","21 Years",{"count":195,"type":22},500,"Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascular and kidney disease in AIs of Southwestern US. The proposed CRIC ancillary cohort study of 500 AIs (AI-CRIC) will rapidly improve our understanding of both potential risk factors for CKD progression, as well as the scope of this disease among AIs. This study leverages the current CRIC study and incorporates the planned activities of the next phase of the study - \"CRIC 2018\" - by implementing contemporary CRIC protocols for kidney and cardiovascular measurement and outcomes.",[198,199,32,98],"Diabetes Mellitus","Chronic Kidney Diseases","2026-05-18",{"date":202,"type":44},"2026-05-20",{"date":204,"type":44},"2020-08-31",{"date":206,"type":22},"2028-06-30",{"name":208,"class":185},"University of New Mexico",3,{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100627491","self-expanding-coronary-sinus-reducer-for-treatment-of-symptomatic-coronary-microvascular-dysfunction-cmd-100627491","NCT07449325","Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","SERRA-I US","Inclusion criteria\n\n1. Older than 18 years of age.\n2. Left ventricular ejection fraction (LVEF) is greater than or equal to 25% within the 12 months before the index procedure. Note: The LVEF must be reassessed after any intervening myocardial infarction. The most recent LVEF assessment is used as the qualifying test for subjects with multiple assessments\n3. Greater than or equal to 30 days of persistent symptomatic coronary microvascular dysfunction (angina pectoris, or equivalent symptoms) (classified as CCS Grade II - IV angina, or NYHA Class 2 or 3 equivalent non-anginal functional impairment) despite optimal medical therapy, as determined by Investigator and confirmed by the Central Screening Committee. Note: Optimal medical management is defined as at least 2 anti-anginal medications or maximally tolerated medical therapy if less than 2 anti-anginal medications.\n4. CFR\\\u003C2.5 measured with continuous thermodilution within 30 days of index procedure. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators. RCA measurements are not permitted for this study.\n\n   Note: CFR should be measured in LAD or LCX if LAD is not feasible. RCA measurements are not permitted for this study\n5. Sustained angina (or equivalent symptoms) reported for at least 2 weeks leading up to the index procedure, as reported via the ORBITA-app.\n6. Willing and able to sign informed consent.\n7. Willing to comply with the specified follow-up evaluations.\n\n   Procedural Angiographic\u002FHemodynamic Inclusion Criteria:\n\n   The following will be assessed during the index procedure to confirm eligibility before an attempt at implantation. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators if not yet obtained in the prior 30 days (see inclusion criteria 4).\n8. Mean right atrial pressure ≤15 mmHg.\n9. The CS anatomy is suitable for implantation at the Investigator's discretion\n\nExclusion Criteria\n\n1. Significant obstructive epicardial disease (greater than 50% diameter stenosis) that can be treated with PCI or CABG as determined by Investigator and confirmed by the Central Screening Committee.\n2. Recent (less than 30 days before index procedure) troponin or CKMB positive acute coronary syndrome (NSTEMI or STEMI) with evidence of ischemia.\n\n   Note: subjects with an elevated troponin or CKMB without acute coronary syndrome may still be considered eligible.\n3. Extra-coronary contributory causes of angina- e.g., untreated hyperthyroidism, anemia (Hgb less than 9 g\u002FdL), uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg despite medications), atrial fibrillation with a rapid ventricular response (consistently greater than 100 bpm despite medications) or other tachyarrhythmia, severe aortic stenosis, decompensated heart failure, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction or asymmetric septal hypertrophy (concentric left ventricular hypertrophy is not an exclusion criterion).\n4. NYHA class IV or decompensated HF or hospitalization due to HF during the 90 days before the index procedure.\n5. Life-threatening rhythm disorders or any rhythm disorders that would require cardiac resynchronization therapy or lead placement in the coronary sinus.\n6. Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second (FEV1) of less than 1.0L or need for home daytime oxygen or regular oral steroids.\n7. Severe valvular heart disease (any valve).\n8. Moderate (TAPSE\\\u003C12) or severe RV dysfunction (TAPSE\\\u003C8) by echocardiography.\n9. A pacemaker electrode\u002Flead is present in the coronary sinus.\n10. Recent implantation of a new pacemaker or defibrillator leads with any electrode in the right atrium within 90 days of the index procedure.\n11. Chronic severe renal failure (estimated eGFR less than 30 mL\u002Fmin\u002F1.73m2 or equivalent) or subjects on chronic dialysis.\n12. Known allergy to titanium, nickel, platinum, tungsten, or known inability to tolerate contrast medium\n13. Any clinical condition that might interfere with the trial protocol or the subject's ability to be compliant with the trial protocol (e.g., active alcohol or illicit substance use, cognitive decline).\n14. Currently enrolled in another investigational device or drug trial that has not reached its primary endpoint or might clinically interfere with the current trial endpoints or procedures.\n15. Pregnant or planning pregnancy within the next 12 months (females of reproductive potential must have a negative pregnancy test within 7 days of the procedure).\n16. Part of a vulnerable population who, in the investigator's judgment, cannot give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances, or lack of autonomy.\n17. Inability to tolerate dual antiplatelet therapy for 6 months if not on a chronic oral anticoagulant, or inability to tolerate a P2Y12 inhibitor for at least 6 months if on a chronic oral anticoagulant.\n18. Comorbidities limiting life expectancy to less than one year.\n19. Currently hospitalized for definite or suspected COVID-19.",{"count":219,"type":22},30,[94],"VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.",[110,108,32,98,101,223],"Microvascular Angina","2026-05-14",{"date":226,"type":44},"2026-05-15",{"date":228,"type":22},"2026-04",{"date":230,"type":22},"2027-12",{"name":232,"class":51},"VahatiCor, Inc.",2,{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":241,"maxAge":19,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":252,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":125},"100562453","changes-in-plaque-characteristics-after-short-term-statin-therapy-as-assessed-with-coronary-ct-100562453","NCT06603363","Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","INTENSE","Inclusion Criteria:\n\n* patients referred for coronary computed tomography angiography (CTA)\n* females aged 45-75 years and males aged 40-75 years\n* presence of at least mild coronary atherosclerosis (luminal stenosis \\>25%, with at least one partially calcified or non-calcified plaque)\n* statin-naive patients\n* ability to understand and provide written informed consent\n* FFR-CT value ≥0.75, indicating the absence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* contraindications to coronary CTA\n* current or prior treatment with statins or other lipid-lowering agents (e.g., ezetimibe)\n* age below 45 years in females or below 40 years in males\n* age above 75 years in both sexes\n* pregnancy or breastfeeding\n* type 1 or type 2 diabetes mellitus\n* history of coronary stent implantation or coronary artery bypass grafting\n* history of myocardial infarction\n* ≥70% luminal stenosis in the proximal left anterior descending artery (LAD), or ≥50% stenosis in the left main (LM) coronary artery\n* FFR-CT value \\\u003C0.75 in any coronary artery\n* elevated serum alanine aminotransferase (ALT) levels (\\>3× the upper limit of normal)\n* elevated serum creatine kinase (CK) levels (\\>3× the upper limit of normal)\n* LDL cholesterol level \\>5 mmol\u002FL\n* renal failure or significantly impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* ongoing oncological treatment\n* active liver disease\n* known hypersensitivity to any excipients of the investigational product\n* concomitant treatment with the combination of sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir\n* concomitant treatment with cyclosporine\n* women of childbearing potential not using adequate contraception\n* presence of myopathy","45 Years",{"count":243,"type":22},140,[94],"INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for rosuvastatin) among statin-naive patients referred to coronary CT angiography due to stable chest pain, followed for 24 months by using a photon-counting detector CT (PCD-CT).\n\nINTENSE Trial aims 1) to assess the effect of short-term intensified statin therapy on coronary anatomy and physiology using PCD-CT and 2) to determine the impact of short-term, intensified statin therapy on coronary plaque morphology and hemodynamics to identify statin responder and non-responder patients in addition to testing the hypothesis of \"plaque memory\" after the 24-month follow-up period.",[107,247,248,249,250,32,98,99,101,251],"Atherosclerotic Plaque","Coronary Computed Tomography Angiography","Statin Therapy","Multidetector Computed Tomography","Hyperlipidemia",[253,254,255,256,257,258,259,260],"coronary artery disease","stable chest pain","intermediate pretest probability","explanatory randomised controlled trial","coronary computed tomography angiography","photon-counting detector CT","atherosclerotic plaque","statin therapy","2026-05-08",{"date":263,"type":44},"2026-05-13",{"date":265,"type":44},"2025-05-28",{"date":267,"type":22},"2028-12-15",{"name":269,"class":185},"Prof. Maurovich-Horvat Pál",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":278,"sex":17,"minAge":279,"maxAge":19,"enrollmentInfo":280,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":282,"conditions":283,"keywords":298,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":125},"100346729","psychosocial-environmental-and-chronic-disease-trends-in-puerto-rico-100346729","NCT03794531","Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico","Puerto Rico Observational Study of Psychosocial, Environmental, and Chronic Disease Trends","PROSPECT","Inclusion Criteria:\n\n1. Age 30-75 years old at the time of enrollment\n2. Non-institutionalized\n3. Living in PR at the time of the first interview and the year before and not planning to move from the island within 3 years\n4. Able to answer questions without assistance\n5. Living in a stable dwelling\n\nExclusion Criteria:",true,"30 Years",{"count":281,"type":22},2500,"The overall goal is to identify trends and longitudinal associations in psychosocial, food-related, and cardiometabolic risk factors that can guide public health priorities and future research needs aimed at reducing cardiovascular-related disparities in Puerto Rico. To this end, investigators will establish 'PROSPECT: Puerto Rico Observational Study of Psychosocial, Environmental, and Chronic disease Trends', an island-wide, longitudinal population cohort of 2,500 adults (30-75 years) in PR recruited with a community-wide sampling strategy, and assessed in a network of several partner clinics across the island. The study will collect comprehensive data on multiple psychosocial, dietary, and food-related factors, CVD biological markers, and medical record data, with follow-up at 2-years, and will assess variations by urban-rural area and by timing before-after Maria.",[32,284,285,286,287,288,98,289,290,291,292,293,294,295,296,297],"Type2 Diabetes","Hypertension","Obesity","Dyslipidemias","Metabolic Syndrome","Chronic Disease","Inflammation","Psychological Stress","Physiological Stress","Depressive Symptoms","Coping Behavior","Diet Habit","Lifestyle","Food Insecurity",[299,300,301,302,303,304,305,306,307,308,309,310,311],"Hispanics\u002FLatinos","Minority health","Puerto Rico","Cardiovascular disease","Cardiometabolic health","Chronic disease risk factors","Disaster research","Caribbean and Latin America","Population health","Prospective study","Allostatic load","Food insecurity","Longitudinal study","2026-04-30",{"date":314,"type":44},"2026-05-05",{"date":316,"type":44},"2019-03-01",{"date":318,"type":22},"2029-04-30",{"name":320,"class":185},"Harvard School of Public Health (HSPH)",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":350},"100457650","ablation-of-consecutive-atrial-tachycardia-100457650","NCT05239364","Ablation of Consecutive Atrial Tachycardia","Ablation of CONseCutive atriaL Tachycardia gUided by Ultra-high-DEnsity Mapping","CONCLUDE","Inclusion Criteria:\n\n* Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery\n* Surface ECG-documentation of AT as primary clinical arrhythmia\n* ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* No previous atrial fibrillation ablation procedure or cardiac surgery\n* Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment\n* History of hemorrhagic diathesis or other coagulopathies\n* Contraindications for oral anticoagulation\n* Hyper- or hypothyroidism\n* Has any condition that would make participation not be in the best interest of the subject",{"count":330,"type":22},100,[94],"Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of patients is known to show various tachycardias and recurrences occur in a noticeable number of cases. With the availability of novel ultra-high-density mapping techniques characterization and understanding of AT mechanisms and underlying substrate can be improved. Aim of this prospective, multi-center, randomized study is to compare a standard AT ablation approach versus minimalized ablation of the clinical AT in regards to arrhythmia free survival.",[334,32,173,335],"Heart Arrhythmia","Atrial Tachycardia",[337,338,339,340,341],"Atrial fibrillation","Atrial tachycardia","Pulmonary vein isolation","Electroanatomical mapping","High density mapping","2026-04-27",{"date":312,"type":44},{"date":345,"type":44},"2020-12-22",{"date":347,"type":22},"2027-06",{"name":349,"class":185},"Evangelical Hospital Düsseldorf",6,{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":125},"100566823","sternal-plating-high-risk-100566823","NCT06660186","Sternal Plating High Risk","Randomized Trial of Rigid Plate Fixation Versus Wire Cerclage in High-Risk Sternotomy Patients","Preoperative Inclusion Criteria\n\n* Adults (age range: 18-89)\n* Undergoing cardiac surgery through sternotomy\n\n  -≥2 risk factors:\n* Diabetes mellitus\n* Severe COPD\n* Chronic steroid use\n* Immunosuppression\n* Redo sternotomy\n* Chronic\n* Kidney disease with GFR \\>30 ml\u002Fmin per 1.73m2\n* Radiation therapy\n* BMI≥35\n* High-risk of delirium\n* Heavy alcohol use\n\nPreoperative Exclusion Criteria\n\n* Active malignancy\n* Chronic narcotic use\n* NYHA Class IV\n* Known nickel metal allergy\n* Compliance concern\n* eGFR\\\u003C30 ml\u002Fmin per 1.73m2\n* Involvement in another interventional clinical trial (non-registry)\n* Any criteria precluding RPF or WC\n\nOperative Inclusion Criteria\n\n* Off-midline sternotomy\n* BITA grafting\n* CPB time ≥120 minutes\n* Transverse sternal fracture\n\nOperative Exclusion Criteria\n\n* Emergent or emergent salvage surgery\n* Non-standard sternotomies\n* Sternotomy with bony margin \\\u003C2 mm\n* Bleeding\n* Delayed sternal closure\n* Surgical complications\n* Any criteria precluding RPF or WC","89 Years",{"count":360,"type":22},250,[94],"Participants are being invited to participate in a research study at University Hospitals because they have heart disease and are scheduled for open heart surgery. Currently, UH cardiac surgeons close the sternum (or breastbone) after a sternotomy (procedure that allows a doctor to reach the heart and blood vessels) with either a rigid plate fixation Sternal Plate or a Wire Cerclage. However, the study team would like to further evaluate these two techniques. Any volunteer over the age of 18 who is at an increased risk for developing sternal wound complications may be eligible to participate.",[32],[365,366,367,368,103,369],"Cardiac Surgery","Wound Complication","Rigid Sternal Fixation","Sternal Infection","Non-union","2026-04-24",{"date":312,"type":44},{"date":373,"type":44},"2026-03-12",{"date":375,"type":22},"2027-06-30",{"name":377,"class":185},"University Hospitals Cleveland Medical Center",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":278,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":233},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",{"count":386,"type":22},1000,"Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[389,31,32,98,390,391,392,393,394,395,396,397,398,399,400,401,402],"Arrhythmogenic Right Ventricular Cardiomyopathy","Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Sarcoidosis","Cardiac Arrhythmia","Cardiac Sarcoidosis","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":342,"type":44},{"date":406,"type":44},"2018-02-09",{"date":408,"type":22},"2027-03",{"name":410,"class":185},"Mayo Clinic",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":125},"100543632","to-compare-and-evaluate-the-efficacy-and-safety-between-ts-rf-system-and-brk-transseptal-needles-used-for-transseptal-puncture-for-left-atrial-access-100543632","NCT06358391","To Compare and Evaluate the Efficacy and Safety Between TS-RF System and BRK Transseptal Needles Used for Transseptal Puncture for Left Atrial Access.","A Prospective, Multi-center, Randomized, Single-blind, Non-inferiority Confirmatory Study Designed to Compare and Assess Efficacy and Safety Between \"TS-RF System Consisting of a Electrosurgical System, General-purpose (TS-RF Generator) and a Electrosurgical System Electrode, Hand-controlled, General-purpose, Single-use (TS-RF Needle)\" and \"Needle, Puncture, Single-use (BRK Transseptal Needle)\", Both of Which Are Used for the Transseptal Puncture Performed to Enable Left Atrial Access for the Treatment of Symptomatic Arrhythmia and Mitral Stenosis","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Diagnosed with one of the following cardiac disorders as shown in the medical record:\n\n   \\[Symptomatic arrhythmia\\]\n   * \"Atrial fibrillation\" diagnostics (including paroxysmal, persistent, long-standing persistent and permanent atrial fibrillation)\n\n     * Diagnostic criteria: atrial fibrillation lasting ≥ 30 seconds as a result of standard 12-lead electrocardiogram (ECG) or single-lead ECG\n     * ECG feature: irregular R-R interval, lack of visible P waves, irregular atrial activation\n     * Symptoms: fatigue, palpitation, dyspnea, chest discomfort, sleep disorders, mental stress\n     * Type:\n\n       * Paroxysmal atrial fibrillation (stopping within 48 hours without any treatment; restoring the sinus rhythm with cardioversion within 7 days)\n       * Persistent atrial fibrillation (persisting for ≥ 7 days; including sinus rhythm restoration with direct-current cardioversion (DCC) or pharmacological cardioversion after the persistence)\n       * Long-standing persistent atrial fibrillation (persisting for ≥ 1 year; including cases requiring cardioversion)\n       * Permanent atrial fibrillation (The patient and healthcare provider accept atrial fibrillation and do not consider cardioversion; if cardioversion is considered, the atrial fibrillation is reclassified as long-standing persistent atrial fibrillation)\n   * \"Paroxysmal Supraventricular Tachycardia\" diagnostics\n\n     = Clinical feature: The heart beats regularly 150 to 200 times per minute; the start and end of paroxysmal supraventricular tachycardia are clearly recognizable; these occur unexpectedly and stop abruptly.\n   * \"Ectopic Atrial Rhythm Tachycardia\" diagnostics\n\n     = Clinical feature: Heart rhythm of less than 250 beats per minute; morphologic difference from P waves in the sinus rhythm; P waves that precede QRS waves are identifiable.\n   * \"Ventricular Tachycardia\" diagnostics = Clinical feature: Wide QRS waves appear in succession with a rapid ventricular rate of ≥ 100 beats per minute; the patients is diagnosed with persistent ventricular tachycardia if tachycardia persists for ≥ 30 seconds but with non-persistent ventricular tachycardia if not applicable.\n   * \"Arrhythmia requiring left atrial access, including left atrial appendage occlusion, in the left atrium\" diagnostics = Clinical feature: moderate or higher risk of stroke, risk of bleeding, or contraindication to anticoagulation therapy\n\n   \\[Symptomatic mitral stenosis\\]\n\n   -\"Mitral Stenosis requiring percutaneous mitral valvuloplasty through left atrial access\" diagnostics\n   * Diagnostic criteria: confirmation of mitral stenosis with echocardiography and assessment of severity\n   * Symptoms: dyspnea; shortness of breath even at rest or inability to sleep in a supine position if dyspnea worsens; may accompanied by coughing, sputum, and chest pain.\n3. Understood this clinical study and voluntarily signed the informed consent form (ICF)1\n\nExclusion Criteria:\n\n\\[For symptomatic arrhythmia and mitral stenosis\\] If any of the following applies, you cannot participate in this clinical trial.1,26,37,45,46\n\n1. Patients with significant congenital heart defects, such as atrial septal defect or pulmonary vein (PV) abnormalities (excluding patent foramen ovale (PFO)).\n2. Thrombus in the left atrium\n3. Atrial fibrillation to reversible causes (e.g. hyperthyroidism, thoracic surgery)\n4. Known or suspected left atrial myxoma.\n5. Unstable angina.\n6. Pre-existing hemidiaphragmatic paralysis\n7. Contraindication to anticoagulation or radiocontrast materials\n8. liver disease (including active hepatitis) and kidney disease.\n9. Cerebral ischemic event (strokes or TIAs) during the six-month interval preceding the consent date\n10. Malignant tumors or hematological diseases or life expectancy of less than one (1) year.\n11. Currently participating or anticipated to participate in any other clinical trial of a drug, device or biologic that has the potential to interfere with the results of this study\n12. Unwilling or unable to comply fully with study procedures and follow-up\n13. A pregnant woman, a woman planning on becoming pregnant, or a lactating woman.\n14. Ineligible for study participation in the judgment of the investigator.",{"count":419,"type":22},70,[94],"The purpose of this study is to compare and assess efficacy and safety between the study device \"TS-RF system consisting of a electrosurgical system, general-purpose (TS-RF Generator) and a electrosurgical system electrode, hand-controlled, general-purpose, single-use (TS-RF Needle)\" and the control device \"needle, puncture, single-use (BRK Transseptal needle)\", both of which are used for the transseptal puncture performed to enable left atrial access for the treatment of symptomatic arrhythmia and mitral stenosis and then to demonstrate that the study device is non-inferior to the control device.",[173,174,32],[424,425,426,427],"Transseptal puncture","Left atrial access","Transseptal catheterization","Radiofrequency","2026-04-21",{"date":370,"type":44},{"date":431,"type":44},"2024-08-21",{"date":433,"type":22},"2026-10-31",{"name":435,"class":51},"Starmed",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":450,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":462},"100302428","randomization-of-single-vs-multiple-arterial-grafts-100302428","NCT03217006","Randomization of Single vs Multiple Arterial Grafts","Randomized Comparison of the Clinical Outcome of Single Versus Multiple Arterial Grafts: the ROMA Trial","ROMA","Inclusion Criteria:\n\n* Primary isolated CABG patients with disease of the left main coronary artery and\u002For of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.\n\nExclusion Criteria:\n\n* Age \\> 70 years\n* Single graft\n* Emergency operation\n* Evolving myocardial infarction within 48 hours of surgery\n* Left ventricular ejection fraction of \\\u003C 35%\n* Any concomitant cardiac or non-cardiac procedure\n* Previous cardiac surgery\n* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduce life expectancy to less than 5 years.\n* Inability to use the saphenous vein or to use both radial and right internal thoracic arteries\n* Anticipated need for coronary thrombo-endarterectomy\n* Planned hybrid revascularization","70 Years",{"count":446,"type":22},4300,[94],"The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and\u002For repeat revascularization. The secondary hypothesis is that in patients undergoing primary isolated non-emergent CABG, the use of two or more arterial grafts compared to a single arterial graft is associated with improved survival.\n\nProspective event-driven unblinded randomized multicenter trial of at least 4,300 subjects enrolled in at least 25 international centers. Patients will be randomized to a single arterial graft (SAG) or multiple arterial grafts (MAG). Patients will be randomized in a 1:1 fashion between the two groups. Permuted block randomization with random blocks stratified by the center and the type of second arterial graft will be used to provide treatment distribution in equal proportion.",[107,32],[451,452,453],"coronary artery bypass surgery","multiple arterial graft","radial artery graft","2026-04-20",{"date":428,"type":44},{"date":457,"type":44},"2018-01-07",{"date":459,"type":22},"2030-01-01",{"name":461,"class":185},"Weill Medical College of Cornell University",59,{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":471,"minAge":18,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":479,"overallStatus":494,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":4},"100635234","womenfocused-education-in-cardiac-rehabilitation-wecare-pilot-rct-100635234","NCT07550036","WomenFocused Education in CArdiac REhabilitation (WECARE) Pilot RCT","Women Education in CArdiac REhabilitation (WE CARE): a Pilot Randomized Controlled Trial for Effectiveness, Implementation, Utilization, and Acceptability of Cardiac College for Women Across Canada","WE-CARE","Inclusion Criteria:\n\n* Identify as a woman\n* Aged 18 years or older\n* Enrolled in a participating cardiac rehabilitation program\n* Diagnosis consistent with cardiac rehabilitation eligibility (e.g., coronary artery disease, myocardial infarction, revascularization procedures, spontaneous coronary artery dissection, myocardial infarction with non-obstructive coronary arteries, Takotsubo cardiomyopathy, or heart failure)\n* Able to provide informed consent\n* Able to participate in educational sessions in English or French (site-dependent)\n\nExclusion Criteria:\n\n* Medical, cognitive, or psychiatric conditions that would prevent participation in educational sessions or completion of study questionnaires\n* Inability to access or use online educational sessions or digital materials required for the intervention","FEMALE",{"count":473,"type":22},50,[94],"The goal of this pilot clinical trial is to learn if a women-focused education program can improve knowledge, health, and well-being in women with heart disease who are attending cardiac rehabilitation. It will also help researchers understand if this program can be delivered successfully in different rehabilitation programs.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to deliver this women-focused education program within routine cardiac rehabilitation programs?\n* Do women who receive this program show improvements in heart health knowledge, quality of life, and healthy behaviours?\n\nResearchers will compare women who receive the Cardiac College for Women program plus usual cardiac rehabilitation to those who receive usual cardiac rehabilitation alone to see if the program leads to better outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either the women-focused education program or usual care\n* Attend cardiac rehabilitation as part of their regular care\n* Complete questionnaires at the start and end of the program\n* (If in the intervention group) attend online education sessions and use supporting materials\n* (Optional) take part in a group discussion about their experience after completing the program",[98,32,477,478],"Health Knowledge, Attitudes, Practice","Behavior, Health",[480,481,482,483,484,485,486,487,488,489,490,491,492,493],"Cardiac Rehabilitation","Women's Health","Patient Education","Cardiovascular Disease Prevention","Secondary Prevention","Health Education","Women-Focused Care","Gender-Specific Care","Digital Health \u002F Virtual Care","Self-Management","Health Behaviour Change","Quality of Life","Feasibility Study","Pilot Randomized Controlled Trial","NOT_YET_RECRUITING","2026-04-17",{"date":370,"type":44},{"date":498,"type":22},"2026-09-01",{"date":500,"type":22},"2027-09-01",{"name":502,"class":185},"University Health Network, Toronto",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":278,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":526},"100536957","smartphone-twelve-lead-ecg-utility-in-st-elevation-myocardial-infarction-ii-100536957","NCT06271577","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II (STLEUISII)","STLEUISII","Inclusion Criteria:\n\n* Male or female \\> 18 years of age.\n* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.\n* Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.\n\nExclusion Criteria:\n\n* Inability or refusal of the patient and\u002For the patient's legally acceptable representative to provide written informed consent for any reason.\n* Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and\u002For compromise the quality of the clinical trial.",{"count":386,"type":22},[94],"AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).\n\nRecently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.",[515,516,108,32,98,101,517,138],"Myocardial Infarction","Ischemia","Heart Attack","2026-04-08",{"date":520,"type":44},"2026-04-09",{"date":522,"type":44},"2024-03-12",{"date":408,"type":22},{"name":525,"class":51},"AliveCor",4,{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":542,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":557},"100296681","the-empower-trial---the-carillon-mitral-contour-system-in-treating-heart-failure-with-fmr-100296681","NCT03142152","The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR","Assessment of the Carillon Mitral Contour System® in Treating Heart Failure With Functional Mitral Regurgitation","Inclusion Criteria:\n\n1. Symptomatic heart failure with functional (secondary) mitral regurgitation of at least 1+ (mild) severity\n2. NYHA II, III, or IV\n3. Six Minute Walk distance ≥ 100 meters and ≤ 600 meters\n4. Left Ventricular Ejection Fraction ≤ 50%\n5. LVEDD:\n\n   * ≥ 55 mm (women)\n   * ≥ 57 mm (men)\n6. LVESD ≤ 75 mm\n7. Corrected NT-proBNP \\> 1200 pg\u002Fml measured within 60 days of randomization, and\u002For one or more heart failure hospitalizations within one year prior to consent or one or more outpatient visits for intensification of heart failure therapy within one year prior to consent.\n8. Optimal Guideline directed heart failure medical therapy assessed by the Central Review Committee\n9. Age ≥ 18 years old\n10. Carillon implant can be sized and placed in accordance with the IFU\n11. The subject has been informed of the nature of the trial and agrees to its provisions, including the possibility of randomization to the Control group and returning for all required post-procedure follow-up visits, and has provided written informed consent\n\nExclusion Criteria:\n\n1. Presence of a mechanical or bio-prosthetic mitral valve or, mitral valve annuloplasty, or leaflet repair device\n2. Significant organic mitral valve pathology (e.g., moderate or severe myxomatous degeneration, with or without mitral leaflet prolapse, rheumatic disease, full or partial chordal rupture)\n3. Severe tricuspid regurgitation associated with right ventricular dysfunction and enlargement\n4. Severe mitral annular calcification\n5. Severe aortic stenosis\n6. Expected to require any cardiac surgery, including surgery for coronary artery disease (CAD) or valve disease within one (1) year\n7. Chronic, severe, medical conditions or pathology, other than heart failure, that will prevent likely survival beyond twelve (12) months or any other medical condition that, in the judgement of the Investigator or Central Review Committee, makes the patient a poor candidate for this study\n\n   * An entire list of eligibility is available in the clinical investigational plan",{"count":535,"type":22},300,[94],"The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).",[539,138,540,32,98,541],"Functional Mitral Regurgitation","Mitral Valve Insufficiency","Heart Valve Diseases",[539,543,544,545,546,547,548],"Percutaneous Mitral Valve Repair","Percutaneous Mitral Valve Annuloplasty","Coronary Sinus Annuloplasty","Secondary Mitral Regurgitation","Functional MR","FMR",{"date":550,"type":44},"2026-04-13",{"date":552,"type":44},"2018-01-01",{"date":554,"type":22},"2030-12-31",{"name":556,"class":51},"Cardiac Dimensions, Inc.",92,{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":566,"conditions":567,"keywords":573,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":596,"leadSponsor":598,"locationsCount":599},"100561461","abbott-structural-heart-device-registry-100561461","NCT06590467","Abbott Structural Heart Device Registry","SH-Registry","Inclusion Criteria:\n\n1. Subject is expected to undergo an implant attempt using one or more Abbott Structural Heart devices covered in this Registry or has previously undergone an implant attempt within the timeframes specified in the device-specific appendices.\n2. Subject is willing and able to comply with the site's standard of care follow-up schedule.\n3. Subject is willing to provide appropriate informed consent for Registry participation. For deceased subjects enrolled retrospectively, local regulations and EC\u002FIRB recommendations regarding consent and the protection of personal data must be followed.\n\nExclusion Criteria:\n\n1\\. Subject is participating in another clinical study that would affect the results of this Registry.",{"count":281,"type":22},"The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017\u002F745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.",[32,568,569,570,571,572],"ASD - Atrial Septal Defect","VSD - Muscular Ventricular Septal Defect","PFO - Patent Foramen Ovale","PIVSD - Post Infarct Muscular Ventricular Septal Defect","Valvular Heart Disease",[574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],"Amplatzer","Amplatzer Septal Occluder","Amplatzer Multi-fenestrated (Cribriform) Occluder","Amplatzer Duct Occluder","Amplatzer Piccolo Occluder","Amplatzer Muscular VSD Occluder","Amplatzer Post-Infarct VSD Occluder","Amplatzer Talisman","Amplatzer TorqVue Delivery System","Amplatzer Sizing Balloon","Amplatzer Guidewire","Amplatzer Occluder devices","Surgical Valves","Epic Plus Aortic Valve","Epic Plus Mitral Valve","Epic Plus Supra Aortic Valve","Epic Max Aortic Valve","Bioprosthetic heart valve","Surgical tissue heart valve","2026-04-07",{"date":550,"type":44},{"date":431,"type":44},{"date":597,"type":22},"2039-11",{"name":158,"class":51},28,{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":607,"targetDuration":609,"studyType":170,"phases":4,"briefSummary":610,"conditions":611,"keywords":615,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":624,"locationsCount":125},"100301866","registry-for-the-improvement-of-postoperative-outcomes-in-cardiac-and-thoracic-surgery-100301866","NCT03209674","Registry for the Improvement of Postoperative OutcomeS in Cardiac and Thoracic surgEry","RIPOSTE","Inclusion Criteria:\n\n* all patients eligible for cardiac or thoracic surgery\n\nExclusion Criteria:\n\n* non applicable",{"count":608,"type":22},8000,"2 Months","The registry for the improvement of postoperative outcomes in cardiac and thoracic surgery aims to prospectively collect data in order to test the association between various preoperative and per-operative variables ; and several postoperative outcomes such as mortality, shock, redo surgery, sepsis and extracorporeal life-support.",[32,612,613,614],"Death","Postoperative Complications","Cardiac Complication",[616,617],"Cardiac surgery","Thoracic surgery","2026-04-02",{"date":620,"type":44},"2026-04-03",{"date":622,"type":44},"2012-01-01",{"date":554,"type":22},{"name":625,"class":185},"CMC Ambroise Paré",{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":471,"minAge":18,"maxAge":4,"enrollmentInfo":634,"targetDuration":4,"studyType":23,"phases":636,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":648},"100372032","comparison-of-the-outcomes-of-single-vs-multiple-arterial-grafts-in-women-100372032","NCT04124120","Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women","Randomized Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women (ROMA:Women) Trial","ROMA:Women","Inclusion Criteria:\n\n1. Women patients ≥18 years old.\n2. Isolated coronary artery bypass grafting.\n3. Primary (first time) cardiac surgery procedure.\n4. Significant disease of the left main coronary artery or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.\n\nExclusion Criteria:\n\n* Male gender\n* Single graft\n* Emergency operation\n* Myocardial infarction within 72 hours of surgery\n* Left ventricular ejection fraction \\\u003C 35%\n* Any concomitant cardiac or non-cardiac procedure\n* Previous cardiac surgery\n* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduces life expectancy to less than 5 years.\n* Inability to use the saphenous vein or to use both radial and right internal thoracic arteries\n* Anticipated need for coronary thrombo-endarterectomy\n* Planned hybrid revascularization",{"count":635,"type":22},2300,[94],"The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grafting (SAG).\n\nThe specific aims of ROMA:Women are:\n\nAim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grafting (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,300 women randomized 1:1 to MAG or SAG. Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time.\n\nHypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events.\n\nHypothesis 1.1. The improvement with MAG will be consistent across key subgroups.\n\nAim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated.\n\nHypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG.\n\nHypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG.\n\nHypothesis 2.2. The improvement with MAG will be consistent across key subgroups.",[32,107,639],"Coronary Artery Bypass Grafting","2026-03-31",{"date":642,"type":44},"2026-04-01",{"date":644,"type":44},"2023-04-17",{"date":646,"type":22},"2030-03",{"name":461,"class":185},146,{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":657,"enrollmentInfo":658,"targetDuration":4,"studyType":23,"phases":660,"briefSummary":661,"conditions":662,"keywords":663,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":679},"100539914","investigation-of-the-briovad-system-for-the-treatment-of-left-ventricular-heart-failure-100539914","NCT06310031","Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure","Investigation of a Novel, magNetically Levitated VAD for the Treatment of refractOry Left Ventricular heArT failurE","INNOVATE","Inclusion Criteria:\n\n1. Patient is ≥ 18 years of age.\n2. Patient has received institutional approval for LVAD implantation.\n3. Patient has a body surface area (BSA) ≥ 1.2 m2.\n4. Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.\n5. Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF \\\u003C 30% on inotropes or temporary MCS.\n6. Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters\u002Fmin\u002Fm2, while not on inotropes, and also meets one of the following criteria:\n\n   1. Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or\n   2. Has advanced heart failure for at least 14 days and is dependent on an intra-aortic balloon pump (IABP) or temporary mechanical circulatory support device (MCSD) for at least seven days.\n7. Patient has provided voluntary and informed consent.\n8. Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.\n\nExclusion Criteria:\n\n1. Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis\u002Fsenile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and\u002For pericardial disease.\n2. Patient had a myocardial infarction within seven days of study enrollment.\n3. Patient had cardiothoracic surgery within 30 days of implant with the exception of a procedure to implant temporary MCS: Impella 5.5, Impella CP or TandemHeart.\n4. Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.\n5. Patient has contraindications to warfarin anticoagulation.\n6. Patient has known hypo- or hypercoagulable state \\[e.g., disseminated intravascular coagulation (DIC)\\], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.\n7. Patient is on durable MCS (e.g., LVAD or RVAD).\n8. Planned need for durable or temporary RVAD support concomitant with LVAD implant.\n9. Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an intra-aortic balloon pump, Impella 5.5, Impella CP, or TandemHeart.\n10. Patient is on any form of pre-implant temporary MCS and has a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or plasma free hemoglobin \\> 40 g\u002FdL.\n11. Patient has a history of organ transplantation.\n12. Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.\n13. Patient has a platelet count \\\u003C 50 k\u002Fμl.\n14. Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) \\> 5 cm in diameter.\n15. Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.\n16. Patient has an uncontrolled systemic infection.\n17. Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin \\>1000 ug\u002FL.\n18. Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:\n\n    1. Total bilirubin \\> 3.0 mg\u002FdL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.\n    2. International normalized ratio (INR) ≥ 2.0 or PTT \\> 2.5 times control that is not related to anticoagulation therapy.\n    3. Glomerular filtration rate (GFR) \\\u003C 30 mL\u002F min\u002F1.73 m2 or need for renal replacement therapy.\n    4. Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.\n    5. Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1\u002FFVC \\\u003C 0.7 and FEV1 \\\u003C 40% predicted.\n    6. Mechanical ventilation for more than three days present at the time of study enrollment.\n    7. Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.\n    8. History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.\n    9. Symptomatic cerebrovascular disease and\u002For uncorrected carotid stenosis \\> 80%.\n    10. Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.\n    11. Pre-albumin \\\u003C 15 mg\u002FdL and\u002For albumin \\\u003C 2.5 g\u002FdL.\n19. Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.\n20. Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and\u002For insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.\n21. Patient is participating in an interventional clinical trial that may impact or confound the results of the INNOVATE Trial.","100 Years",{"count":659,"type":22},780,[94],"The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.",[98,32,138],[138,664,665,666,667,668,669,670],"Left Ventricular Assist Device","Ventricular Dysfunction","Heart Disease","Cardiovascular Disease","Heart-assist Devices","Left Ventricular Assist System","BrioHealth Solutions","2026-03-27",{"date":642,"type":44},{"date":674,"type":44},"2024-10-28",{"date":676,"type":22},"2028-12",{"name":678,"class":51},"BrioHealth Solutions, Inc.",37,{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":4,"eligibilityCriteria":686,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":687,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":688,"conditions":689,"keywords":692,"overallStatus":494,"whyStopped":4,"lastUpdateSubmitDate":698,"lastUpdatePostDateStruct":699,"startDateStruct":701,"completionDateStruct":703,"leadSponsor":705,"locationsCount":4},"100630367","bag3-dcm-natural-history-study-100630367","NCT07486752","BAG3-DCM Natural History Study","An Observational Study of Patients With Dilated Cardiomyopathy (DCM) Associated With Pathogenic BAG3 Variants","Key Inclusion Criteria:\n\nSubjects are eligible for inclusion into the study only if all the following criteria apply:\n\nGeneral:\n\n1. Adult patients 18 years or older at the time of providing informed consent (i.e., signing the ICF).\n2. Capable and willing to provide signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and protocol.\n3. Diagnosis of DCM as defined by mild to moderate systolic dysfunction performed within 12 months of enrollment and confirmed by the principal investigator that the DCM is predominantly non-ischemic.\n4. Documentation of a pathogenic or likely pathogenic variant in BAG3 by a CLIA-certified or equivalent genetic testing laboratory.\n5. NYHA class I-III\n\nKey Exclusion Criteria:\n\nAll Cohorts:\n\n1\\. Concurrent enrollment in any other clinical investigation involving use of an investigational agent for any condition at time of enrollment to this study that could confound interpretation of this study results 2. Previous treatment with gene therapy 2. Gene testing indicates that the patient's arrhythmia or cardiomyopathy may be related to a genetic etiology other than BAG3 variant.\n\n4\\. NYHA class IV HF. 5. Presence or requirement for MCS or predicted need for MCS or heart transplantation within 6 months prior to enrollment.\n\n6\\. Prior heart transplantation. 7. Known infection with human immunodeficiency virus (HIV). 8. Unwillingness to comply with study procedures, including follow-up as specified by this protocol, or unwillingness to fully cooperate with the investigator.",{"count":219,"type":22},"The goal of this international observational study is to learn about the natural history of Dilated Cardiomyopathy (DCM) arising from pathogenic BAG3 variants in adult patients ≥18 years of age.",[690,98,32,691],"Dilated Cardiomyopathy (DCM)","Genetic Diseases",[693,694,695,696,697],"BAG3","Dilated Cardiomyopathy","BAG3-DCM","Cardiomyopathy","BCL2-associated Athanogene 3","2026-03-17",{"date":700,"type":44},"2026-03-20",{"date":702,"type":22},"2026-05",{"date":704,"type":22},"2033-03",{"name":706,"class":51},"Rocket Pharmaceuticals Inc.",{"id":708,"slug":709,"hasResults":12,"nctId":710,"briefTitle":711,"officialTitle":711,"acronym":4,"eligibilityCriteria":712,"healthyVolunteers":278,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":713,"targetDuration":715,"studyType":170,"phases":4,"briefSummary":716,"conditions":717,"keywords":724,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":726,"lastUpdatePostDateStruct":727,"startDateStruct":728,"completionDateStruct":730,"leadSponsor":732,"locationsCount":125},"100416731","archival-of-human-biological-samples-in-cu-med-biobank-100416731","NCT04706481","Archival of Human Biological Samples in CU-Med Biobank","Inclusion Criteria:\n\n* Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.\n\nExclusion Criteria:\n\n* Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.",{"count":714,"type":22},10000,"99 Years","CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.",[718,719,32,720,721,722,723],"Healthy","Cancer","Neurological Diseases or Conditions","Kidney Diseases","Diabetes","Other Disease",[725],"Biobanking","2026-03-11",{"date":373,"type":44},{"date":729,"type":44},"2020-01-01",{"date":731,"type":22},"2050-12-01",{"name":733,"class":185},"Chinese University of Hong Kong",{"id":735,"slug":736,"hasResults":12,"nctId":737,"briefTitle":738,"officialTitle":739,"acronym":4,"eligibilityCriteria":740,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":741,"targetDuration":4,"studyType":23,"phases":743,"briefSummary":744,"conditions":745,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":746,"lastUpdatePostDateStruct":747,"startDateStruct":749,"completionDateStruct":751,"leadSponsor":753,"locationsCount":350},"100546825","phase-3-lumason-infusion-vs-bolus-administrations-100546825","NCT06400004","Lumason® Infusion vs. Bolus Administrations","A Phase III Crossover Study to Evaluate Bolus Versus Continuous Infusion of Lumason® in Patients With Suboptimal Unenhanced Echocardiography","Inclusion Criteria:\n\n* Are at least 18-years old;\n* Have suboptimal LV EBD, defined as ≥2 adjacent segments in any apical view that cannot be visualized, at pre-contrast echocardiogram;\n* Provide their written informed consent and are willing to comply with protocol requirements.\n\nExclusion Criteria:\n\n* Patient has severe congestive heart failure (class IV according to the classification of the New York Heart Association);\n* Patient has uncontrolled angina (i.e., uncontrolled on medication);\n* Patient had a recent myocardial infarction (within the last 3 days and not stabilized);\n* Patient has severe arrhythmia, that in the opinion of the Investigator, would interfere with the study conduct;\n* Patient has severe pulmonary hypertension, that in the opinion of the Investigator, would interfere with the study conduct;\n* Patient had been treated with any other contrast medium, either intravascular or orally, within 48 hours prior to the first administration;\n* Has any known allergy to one or more of the ingredients of the investigational product;\n* Is pregnant or lactating. Exclude the possibility of pregnancy by: testing on site (serum or urine βHCG) prior to the start of investigational product administration; surgical history (e.g., tubal ligation or hysterectomy); post-menopausal with a minimum 1 year without menses;\n* Has previously entered the study or have received any other investigational drug within 30 days prior to admission in this study;\n* Is determined by the Investigator that the patient is clinically unsuitable for the study.",{"count":742,"type":22},106,[25],"A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason® versus the bolus administration of undiluted Lumason® for degree of LVO and assessment of LV EBD (co-primary endpoints).",[32],"2026-03-04",{"date":748,"type":44},"2026-03-05",{"date":750,"type":44},"2024-07-10",{"date":752,"type":22},"2026-12-31",{"name":754,"class":51},"Bracco Diagnostics, Inc",{"id":756,"slug":757,"hasResults":12,"nctId":758,"briefTitle":759,"officialTitle":760,"acronym":761,"eligibilityCriteria":762,"healthyVolunteers":278,"sex":17,"minAge":18,"maxAge":763,"enrollmentInfo":764,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":765,"conditions":766,"keywords":767,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":778,"lastUpdatePostDateStruct":779,"startDateStruct":780,"completionDateStruct":782,"leadSponsor":784,"locationsCount":209},"100573958","health-electronic-assessment-of-risks-and-trends-using-biometric-equipment-and-technology-100573958","NCT06753045","Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology","Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology: HEARTBEAT","HEARTBEAT","Inclusion Criteria:\n\n* Patients with at least one cardiovascular disease (heart failure, cardiac arrhythmias, chronic kidney disease, coronary artery disease, history of stroke\u002FTransient Ischemic Attack (TIA), or diabetes mellitus).\n* Patients visiting a primary care provider for any reason without any of the previously mentioned cardiovascular diseases. (Healthy cohort, limited up to 500 patients throughout the study).\n\nExclusion Criteria:\n\n* Participants who cannot read, speak, and\u002For understand English.\n* Participants with cognitive impairments who are unable to give informed consent or sign their HIPAA form.\n* Participants with cognitive impairments affecting their ability to be compliant with wearing and maintaining wearable devices.\n* Participants who are pregnant.\n* Participants with tattoos, scars, or skin adhesions that would not allow for Photoplethysmography (PPG) recordings to be collected from a wrist-worn device.\n* Participants with neurological disorders that may interfere with device signal quality (e.g., hand tremors).\n* Participants with a pacemaker.\n* Participants with allergies to watch and\u002For wristband materials.\n* Participants with known plans to permanently leave the state of Louisiana within the observational period.\n* Participants who have no known medical history with any of the enrolling institutions.\n* Patients without a compatible smartphone (iOS 13 \\& Android 11 at minimum).","120 Years",{"count":714,"type":22},"This is a phase 0, non-interventional, longitudinal, electronic data capture (EDC) study to facilitate the HEARTBEAT Study project has set out to explore the potential use of smartwatches in collecting and analyzing biometric data to improve the detection, identification, and understanding of cardiovascular diseases and related conditions by SAMSUNG and Tulane. The study will include up to ten thousand adult subjects tasked with wearing a smartwatch to collect digital biomarker data over a 1 year period. Concurrent to smartwatch data collection, subjects will be instructed to complete questionnaires via the Huma Decentralized Clinical Trials (HUMADCT) platform. There are no investigational drugs or interventions administered as part of this study.",[32],[768,769,770,771,772,773,774,337,775,776,777],"Heart failure","Coronary artery disease","Stroke\u002FTIA","Diabetes mellitus","Chronic kidney disease","Cardiac arrhythmias","Smart watch","A-fib","Artificial intelligence","Machine learning","2026-03-03",{"date":748,"type":44},{"date":781,"type":44},"2024-10-08",{"date":783,"type":22},"2027-10",{"name":785,"class":185},"Tulane University"]